So 2022 has been one of the most challenging years for investors and Traders in the stock market since the Great Recession era. It does not help that 2020 and 2021 happen to be one of the easiest and most exhilarating periods ever. The contrast year over year has quite frankly been insane. You flip from Euphoria and endless optimism and now you've hit a complete brick wall.

2022 is a year of getting your rear end cheek hairs ripped out one by one day after day and the Ripper laughing about it. Don't worry, they'll grow back. It's only transitory. There's this tweet that circulated this morning that shows the heaviest objects in the universe.

You have the sun, you have the neutron star, you have the black hole, and then you have the markets in 2022. And so in many ways Market participants are looking to move on and are looking at 2023.. However, there's big debate over what 2023 is going to look like. According to a new CFO survey, a soft Landing is a fairy tale and the Dow is going to go back down to the Stone Agents Quote: More than 80 percent of respondents to the Q4 survey.

Expect a recession in 2023. That percentage has increased quarter over quarter as more CFOs pushed back earlier forecasts that the economy already had entered a recession. CFOs are divided on the timing with equal percentages 43 percent saying the recession will hit in the first half or second half of the year. So 80 percent, 80 percent day of respondents expect a recession in 2023..

now a lot of people are arguing hey, okay, well wait a second. Charlie Sure, General Business Leaders and CFOs and people on Main Street Well, the people that are actually interacting in the Main Street economy. they think a catastrophe is coming in 2023, but pretty much every major Bank thinks 2023 is going to be a year of increased earnings, increased profitability, and a higher closing number of all major indices by year end. So who is right here? Analysts and investment sales people Or the actual Business Leaders The actual particip depends in the direct economy.

Here are some of the price targets that we are seeing for the S P 500 in 2023. Keep in mind that the S P 500 is at 3 800 as of today. So fun. Strat's Tom Lee sees the S P rallying to 47.50 And if you don't know, Tom Lee Tomley is basically an analyst that took the glasses half full analogy to a whole other level.

The glass could be empty and broken and on the ground and he'd be like yeah, but at least there was some water in that at some point. So bullish. And then you have Deutsche Bank Yaya Deutsche at 4500 Oppenheimer at 4400 Stifel Noculus at 4300 Jeffries at 4200 JP Morgan at 4200 Wells Fargo 4200 Evercore Isi for 150 Canter Fitzgerald at 4100 RBC Capital 4100 Mizuhu at 4100 credit Suites 40 50 B of A 4000 Citigroup 4 000 Goldman Sachs 4000 HSBC 4000 Morgan Stanley 3900 Scotia Bank 3900 And then you go below current S P 500 levels and you find Barclay Society General and BNP Parabass. But overall, for the most part, you have almost every major firm suggesting higher targets for 2023 or at the very least, flat overall.

Now the problem is of course, the way that they are calculating these numbers overall for the overall index and for individual companies is based on what they see as company earnings for the upcoming year, What they see companies bringing back home to the bottom line, and the problem with that is that their earnings expectations across nearly all Industries barely adjusted downward at all. And if the vast majority of Business Leaders are correct and we do see a recession next year Well History says the average earnings per share decline is 29.5 percent in recessions, not flat, not up, not slightly down, but on average negative 29 Down Yes, the S P is down in terms of an equity valuation level like 20 year to date, but this is talking about actual earnings and earnings recession where earnings are down on average 29.5 percent in recessions. Yet analysts have been very, very slow to adjust earnings expectations and net in an effect. they're still expecting earnings to go up in 2023.

So 2023 is going to be a growth year, not a contraction year, not a flat year according to the average consensus on Wall Street The fact of the matter Is that if we see even half even half of the historical earnings per share decline, then that means that these analyst price targets will be proven to be Fugazi Moon Boy numbers. And in fact, if you look at the last two major crises that happen during a tightening cycle the Great Recession and the.com bust while those saw an earnings per share change of negative 91.9 percent oof and negative 54 respectively with seven quarters and five quarters of consecutive earnings per share decline respectively. So the idea that the consensus on Wall Street is trying to sell us is that this time is different. This time we can raise rates and Titan faster than ever before and guess what you get in return? Well, almost no pain and perhaps even solid growth.

Perhaps gravity no longer exists in the stock market, because ooh, this time everything's all different. Survey shows that analysts aren't just guiding against history, but also guiding against Business Leaders themselves CFOs The people most informed on financial conditions within major industries and actually running businesses and making the big decisions instead of just running analyst firms and allocating Capital based on some data and some biased incentives to say nice things to your clients so they continue to invest with you. Okay, now before we get into the rest of the video, a quick word from pre-recorded Charlie and today's sponsor MooMoo today's video is brought to you by Mumu and the now up to 20 free stocks that you can get if you sign up and deposit using our link down below. Let's be real in this market.

the difference between success and failure is having reliable information and a powerful trading platform that has your back and guess what? Mumu offers you exactly that. For starters, MooMoo helps you find stocks that match your strategy with their state-of-the-art customizable screener. MooMoo helps you gain detailed insights into price action such as with their Free level 2 data that has 60 levels for bid. Ask prices that provide visibility of a stock liquidity, supply and demand in real time.

there's no delays, real-time quotes refresh every 0.3 seconds. MooMoo helps you speed up your analysis with Advanced analysis and charting tools including over 63 technical indicators and 38 drawing tools that can help you identify new trends. MooMoo also helps you stay ahead of the market with AI support alerts to help you monitor your trades and respond to price action as soon as it happens. Customizable alerts are available to give you Auto notifications based on price, movement and or changes and indications.

Lumo also has your back with real and human Us-based customer service that are ready to answer any questions you may have during trading time. By the way, many Brokers just have useless Bots for customer service. In addition to this, MooMoo is also available globally for users in the United States, Singapore and Australia backed by Futu, a NASDAQ listed Fintech that has been in the finance industry for 10 years. The Futu group of companies has also obtained over 50 Financial Services licenses from Financial Regulators around the globe.

In the US MooMoo is registered with the SEC and Finra and is a member of the Sipc, which means your funds are securely insured up to 500 000.. Anyways, go ahead and give Mumu a try today and if you are a Us-based user, you can get up to 20 free stocks. If you're an Australian user, there's another deal down there where you can get up to 110 Australian dollars cash back if you deposit about a thousand AUD thank you again MooMoo for the sponsorship! Now back to the content. Okay, now back to the content.

So really though this begs the question: who is Right analysts and investment sales people or the actual Business Leaders that they are analyzing? That's like asking who understands flying better Pilots or the shareholders and Equity analysts trying to get people to buy shares in that Airline Obviously, the Pilot's actually flying are going to understand flying and weather conditions and the situation up there in the sky more than the equity shareholders and Equity partners. And to add to that with another analogy, who is more likely to tell you the truth about the value of, say, a real estate property, a home appraiser you hired, or the seller's real estate agent obviously the seller's age will say whatever they need to sell you the house because that's their incentive structure and that's their job and this is exactly what is happening on. Wall Street Wall Street will only acknowledge the minimum that they have to. Oh okay, maybe we're gonna have a little bit of a Slowdown but earnings are still going to go up year over year, so don't you worry, buy our funds.

The fact of the matter is that they need they need to sell you on their investing and they're investing prowess as fast as possible. Because their businesses have been decimated this year, they need you to invest in them even if this is still halfway, only down the downtrend because if they can't get you invested, they lose out on tons and tons of fees for your assets under management. The Wall Street Journal Just reported that Bankers are bracing for big pay cuts with Revenue down some 40 for investment. Banks Bonuses are expected to fall about 30 percent.

So Wall Street wants to get more deals and in order to get more deals, they have to tell people that things are going to be A-Okay That's going to be perfect. Never seen it like this before. It's going to be fantastic. Go ahead and give us your money.

Go ahead and give us your deals. This is a great time. Next Baby Formula. So Baby Formula is going to be facing tariffs again in 2023.

If you recall. We had a massive baby formula shortage in 2022 and this led to widespread awareness that the baby formula industry in the US is an oligopoly of like three companies who control the entire Market Abbott Gerber and Ruckett Charlie How can you have a baby formula shortage in the wealthiest, most powerful country in the history of Earth Well, in the US, we have this problem where a wealthy connected corporations tend to use politicians to help them create monopolies and oligopolies Crush small businesses and of course protect them from competition internationally and that creates a ton of inefficiencies and the everyday citizen gets screwed again and again because of politicians that want to get their hands in every little piece of business in the United States and want to make sure they get their little donations so they can continue to centrally plan our economy and baby formula. One of the biggest ways this is done is by putting huge tariffs on International imported formula, making it so people have to choose the domestically produced ones. The other way is by creating regulations that are so hard and expensive to to meet that it makes it impossible for smaller players to compete so a few players get to control basically the entire Market.

However, because of the shortage this year, Congress went and waived the tariffs which can be as high as 17.5 percent and this made a big stinking difference according to the Wall Street Journal tariff wavers doubled the number of Manufacturers selling baby formula in the U.S And while this has improved, the supply and the overall issues with domestic producers have improved as well. While the fact of the matter is that out of stock levels are still elevated historically and many parents are reporting empty shelves on major grocery stores. On top of that, costs are extremely high on top of everything else that is more costly than it was last year. Yet, you have the industry already going and urging lawmakers to let the Tariff suspensions expire and if they expire, formula will once again be made more expensive and be made harder to find.

In some cases, protectionism with trade can make sense and we should favor our own Industries but not when these industries are operating like inefficient cartels within the country and even smaller businesses within that same country get quashed when that happens. What that means is that parents are going to have to pay a ton more to get what in many cases is a worse product. If Government played, Fair U.S oligopoly companies wouldn't be so relaxed at having an inferior product or inferior operations and we could get some real competition. It's not like the baby food is coming from an economic adversary, most of it is coming from European countries, with the UK being one of the biggest countries that, quite frankly, like us, have very high if not higher labor costs and higher costs of doing business overall with different regulations and are countries that quite frankly are businesses here in the U.S could easily beat if they didn't have the government to automatically pick them as winners and screw the American Consumer by allowing them to get away without being competitive at all.

The idea that you're going to let suspensions expire after a year where inflation has already ravaged the everyday person and many are about to lose their jobs is atrocious. This will only make baby formula more expensive and worse in the inflation problem and further embolden the failed industry to quash even more domestic competition that would force it to actually act like a proper business. And this is happening in a lot of Industries folks. Not just baby food, but this is one of the most apparent for a capitalist country.

We sure have a lot of central planning from government and government-appointed Central Bankers don't we next place? So one of our briefing plays, kala more than tripled this morning. We briefed on it at about 6 41 a share and it ran to 1748 at highs. Reason The FDA had accepted their end application for their Pced treatment. Pced is a defect and complication of the cornea, and according to the FDA website, an investigator end is submitted by a physician who both initiates and conducts an investigation and under whose immediate Direction the investigational drug is administered or dispensed.

A physician might submit a research End to propose studying an unapproved drug or an approved product for a new indication or in a new patient population. So in English the fact that this end was accepted by the FDA paves the way for the company to focus on clinical execution and initiate their next phase trial step. As you know, the FDA trials are extremely difficult to get through, so every phase past gets investors and speculators excited and that's what we saw this morning. Now takeaways, pay attention to companies who have drugs in their pipelines and companies that drop good FDA news in the extended hours.

If you find them early enough, you may be able to play them before the rest of the market even finds out. Now if you are looking to join us in zip code U to get access to our daily morning briefings and other resources, you can find the link to that below. We do our best to find catalysts each and every Market open morning that have potential trading opportunities. This one was a successful one, but you can also do this on your own.

wake up every morning, make a full spreadsheet, find different patterns and characteristics, track which companies are coming out with new treatments, or are in some phase of the FDA process, and then consistently follow up with them every morning. Usually the Catalyst drop in the extended hours. Now, of course we do have the resource for you if you see value in it, but that's only if you are ready to join us and our team next. I'm watching Tgtx very closely.

It's been beaten down so massively and short interest has ballooned 28 in the last three months. This is a clinical stage biotech company whose Biologics license application for UB Uliximab, their therapy for Ms just came successfully out of the FDA process. now for Context shares pumped more than 50 in November after their CEO said the company had started discussions with the FDA ahead of U.S approval for their therapy and they did just end up getting that approval today with a bit of a halt. I am watching very very closely to see how this reacts in the coming days, especially considering the fact that you do have a lot of short interest on this and that could Ricochet to backfire on short sellers days ago Seeking Alpha Contributor flourishing Capital Predicted that the FDA would approve Eubaleximab and that the drug would generate 1 billion in annual sales by the end of 2024..

considering this is a company whose entire market cap is about a billion dollars right now, this is a big stinking deal I Think it sets it up for various rounds of hype rallies and I'm going to be watching it very closely. Anyways, that caps off today's video. Make sure to hit that ravish and like button and subscribe. Make sure to check out the link to MooMoo down below.

Thank you MooMoo for the sponsorship and of course if you do want to join us in zip Trader you I'll put the link to that Below Have a great rest of your day folks and we will see you in the next one.